CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CSL Ltd

Затворен

СекторИндустриални

210.17 0.15

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

209.19

Максимум

210.4

Ключови измерители

By Trading Economics

Приходи

2B

Продажби

-5.7B

2.5B

P/E

Средно за сектора

21.941

38.367

EPS

2.04

Дивидентна доходност

1.39

Марж на печалбата

24.437

Служители

29,904

EBITDA

-2.4B

858M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+35.44% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.39%

2.26%

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-24B

100B

Предишно отваряне

210.02

Предишно затваряне

210.17

Настроения в новините

By Acuity

38%

62%

142 / 459 Класиране в Industrials

CSL Ltd Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.08.2025 г., 03:32 ч. UTC

Значими двигатели на пазара

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

18.08.2025 г., 23:46 ч. UTC

Печалби

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

18.08.2025 г., 22:15 ч. UTC

Печалби

CSL to Cut Up to 15% of Staff in $770 Million Restructure

9.04.2025 г., 09:39 ч. UTC

Значими двигатели на пазара

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

10.02.2025 г., 21:55 ч. UTC

Печалби

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10.02.2025 г., 21:34 ч. UTC

Печалби

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

18.08.2025 г., 23:46 ч. UTC

Пазарно говорене
Печалби

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

18.08.2025 г., 21:52 ч. UTC

Печалби

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

18.08.2025 г., 21:51 ч. UTC

Печалби

CSL to Cut Up to 15% of Staff>CSL.AU

18.08.2025 г., 21:49 ч. UTC

Печалби

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

18.08.2025 г., 21:49 ч. UTC

Печалби

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

18.08.2025 г., 21:48 ч. UTC

Печалби

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

18.08.2025 г., 21:47 ч. UTC

Печалби

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

18.08.2025 г., 21:46 ч. UTC

Печалби

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

18.08.2025 г., 21:45 ч. UTC

Печалби

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

18.08.2025 г., 21:45 ч. UTC

Печалби

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

18.08.2025 г., 21:44 ч. UTC

Печалби

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

18.08.2025 г., 21:43 ч. UTC

Печалби

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

18.08.2025 г., 21:43 ч. UTC

Печалби

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

18.08.2025 г., 21:42 ч. UTC

Печалби

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

18.08.2025 г., 21:42 ч. UTC

Печалби

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

17.06.2025 г., 02:15 ч. UTC

Пазарно говорене

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

9.04.2025 г., 07:01 ч. UTC

Пазарно говорене

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

21.03.2025 г., 02:03 ч. UTC

Пазарно говорене

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11.02.2025 г., 22:30 ч. UTC

Пазарно говорене

Flu Vaccines Proving Problematic for CSL -- Market Talk

10.02.2025 г., 21:40 ч. UTC

Печалби

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10.02.2025 г., 21:19 ч. UTC

Печалби

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10.02.2025 г., 21:13 ч. UTC

Печалби

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10.02.2025 г., 21:12 ч. UTC

Печалби

CSL Interim Dividend US$1.30/Security

10.02.2025 г., 21:12 ч. UTC

Печалби

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Сравнение с други в отрасъла

Ценова промяна

CSL Ltd Прогноза

Ценова цел

By TipRanks

35.44% нагоре

12-месечна прогноза

Среден 283.415 AUD  35.44%

Висок 330 AUD

Нисък 227.5 AUD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за CSL Ltd през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

13 ratings

9

Купи

4

Задържане

0

Продай

Настроение

By Acuity

142 / 459 Класиране в Индустриални

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat